

Please amend the subject application as follows:

IN THE CLAIMS:

Please amend claims 1-3 and 70-72, 77-81, 83-86 to read as follows:

-
- 1. (TWICE AMENDED) A monoclonal antibody which recognizes and binds an N-terminal portion of a Prostate Stem Cell Antigen (PSCA) protein consisting of amino acids 2 through 50 as described in SEQ ID NO:2 . --
- D¹ --2. (TWICE AMENDED) A monoclonal antibody which recognizes and binds a middle portion of a Prostate Stem Cell Antigen (PSCA) protein consisting of amino acids 46 through 109 as described in SEQ ID NO:2 . --
- 3. (TWICE AMENDED) A monoclonal antibody which recognizes and binds a C-terminal portion of a Prostate Stem Cell Antigen (PSCA) protein consisting of amino acids 85 through 123 as described in SEQ ID NO:2. --
-
- 70. (TWICE AMENDED) The monoclonal antibody of claim 69, wherein the chimeric antibody comprises a murine immunoglobulin variable region and a human immunoglobulin constant region. --
- D² --71. (AMENDED) The monoclonal antibody of claim 1, 2 or 3 which is a humanized antibody. --
- 72. (AMENDED) The monoclonal antibody of claim 71, wherein the humanized antibody comprises a human immunoglobulin constant region. --
-
- D³ -- 77. (AMENDED) An immunotoxin comprising the recombinant protein of claim 76 conjugated with a therapeutic agent. --

- 3
D. 3
ent
- 78. (AMENDED) The immunotoxin of claim 77, wherein the therapeutic agent is a radioactive isotope. --
- 79. (AMENDED) The immunotoxin of claim 78, wherein the radioisotope is selected from a group consisting of ^{212}Bi , ^{131}I , ^{90}Y and ^{186}Re . --
- 80. (AMENDED) The immunotoxin of claim 77, wherein the therapeutic agent is a cytotoxic agent. --
- 81. (AMENDED) The immunotoxin of claim 80, wherein the cytotoxic agent is selected from a group consisting of ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethidum bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphtheria toxin, *Pseudomonas* exotoxin (PE) A, PE40, abrin, arbrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, and glucocorticoid. --
-
- 83. (AMENDED) The immunoconjugate of claim 82, wherein the therapeutic agent is a radioactive isotope. --
- 4
D 4
- 84. (AMENDED) The immunoconjugate of claim 83, wherein the radioisotope is selected from a group consisting of ^{212}Bi , ^{131}I , ^{90}Y and ^{186}Re . --
- 85. (AMENDED) The immunoconjugate of claim 83, wherein the therapeutic agent is a cytotoxic agent. --
- 86. (AMENDED) The immunotoxin of claim 85, wherein the cytotoxic agent is selected from a group consisting of ricin, ricin A-chain, doxorubicin,